Letter from the President
We hope you have been enjoying your summer with family and friends. At MRA, we have been busy announcing our latest round of grants, fostering partnerships to expand our reach, and preparing for our next Request for Proposals to advance melanoma research.
In recent weeks, there has been good news for patients, with several new therapies and treatments making headlines. In immunotherapy news, the European Commission recently approved anti-PD-1 agents nivolumab and pembrolizumab for treatment of patients with advanced metastatic melanoma, including in the first-line treatment of the disease. In the United States, the FDA is considering this same indication for each drug, as well as the combination of nivolumab and ipilimumab.
On the targeted therapies front, the Swiss Agency for Therapeutic Products (Swissmedic) recently approved the BRAF/MEK inhibitor combination of vemurafenib and cobimetinib for the treatment of patients with advanced metastatic melanoma. The same combination of therapies is currently under review by the FDA, with a decision expected by November.
Here at MRA, we are pleased to welcome Mary Jo Rogers to the Board of Directors. Mary Jo is a melanoma survivor and will be an invaluable resource to our organization. Below are a few more highlights from our team.
We hope you enjoy these last few weeks of summer, and thank you for your continued support of MRA.
Acting President and CEO